153 related articles for article (PubMed ID: 37769330)
21. Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis.
Jiao D; Zhang J; Zhu J; Guo X; Yang Y; Xiao H; Liu Z
BMC Cancer; 2021 Feb; 21(1):138. PubMed ID: 33549037
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of post-mastectomy adjuvant chemotherapy for the treatment of patients with prognostic stage IB breast cancer: A SEER-based study.
Wang H; Peng Y; Wu J; Chen Z; Zhang H
Asian J Surg; 2023 Sep; 46(9):3634-3641. PubMed ID: 37210259
[TBL] [Abstract][Full Text] [Related]
23. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
24. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea.
Park YH; Karantza V; Calhoun SR; Park S; Lee S; Kim JY; Yu JH; Kim SW; Lee JE; Nam SJ; Aktan G; Marsico M
Breast Cancer Res Treat; 2021 Oct; 189(3):653-663. PubMed ID: 34487293
[TBL] [Abstract][Full Text] [Related]
25. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
26. Tumor subtypes and survival in male breast cancer.
Leone J; Freedman RA; Lin NU; Tolaney SM; Vallejo CT; Leone BA; Winer EP; Leone JP
Breast Cancer Res Treat; 2021 Aug; 188(3):695-702. PubMed ID: 33770314
[TBL] [Abstract][Full Text] [Related]
27. Clinical Characteristics and Prognosis of Pregnancy-Associated Breast Cancer: Poor Survival of Luminal B Subtype.
Bae SY; Jung SP; Jung ES; Park SM; Lee SK; Yu JH; Lee JE; Kim SW; Nam SJ
Oncology; 2018; 95(3):163-169. PubMed ID: 29913459
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics.
Nelson DR; Brown J; Morikawa A; Method M
PLoS One; 2022; 17(2):e0264637. PubMed ID: 35213669
[TBL] [Abstract][Full Text] [Related]
29. T1-2N0M0 Triple-Negative Breast Cancer Treated With Breast-Conserving Therapy Has Better Survival Compared to Mastectomy: A SEER Population-Based Retrospective Analysis.
Li H; Chen Y; Wang X; Tang L; Guan X
Clin Breast Cancer; 2019 Dec; 19(6):e669-e682. PubMed ID: 31375327
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of HER2 status in T1bN0 breast cancer: a nationwide study from the Korean Breast Cancer Society.
Kang YJ; Oh SJ; Choi H; Cho S; Shin CH; Kim C; Woo J; Lee J; Park HK; Lee HB; Noh WC; Kim YS
Breast Cancer Res Treat; 2021 Feb; 186(1):125-134. PubMed ID: 33389401
[TBL] [Abstract][Full Text] [Related]
31. Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer.
Carbajal-Ochoa W; Bravo-Solarte DC; Bernal AM; Anampa JD
Breast Cancer Res Treat; 2024 Jan; 203(2):257-269. PubMed ID: 37833449
[TBL] [Abstract][Full Text] [Related]
32. Survival following radiotherapy in young women with localized early-stage breast cancer according to molecular subtypes.
Liu QQ; Sun HF; Yang XL; Chen MT; Liu Y; Zhao Y; Zhao YY; Jin W
Cancer Med; 2019 Jun; 8(6):2840-2857. PubMed ID: 31016890
[TBL] [Abstract][Full Text] [Related]
33. [Clinicopathological features and prognosis of breast cancer with human epidermal growth factor receptor 2 low expression].
Zhu XJ; Zhang H; Zhang S; Li D; Li X; Xu L; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):243-253. PubMed ID: 37042134
[TBL] [Abstract][Full Text] [Related]
34. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
35. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of androgen receptor expression in HER2-positive and triple-negative breast cancer.
Kucukzeybek BB; Bayoglu IV; Kucukzeybek Y; Yıldız Y; Oflazoglu U; Atahan MK; Taskaynatan H; Alacacioglu A; Yigit S; Tarhan MO
Pol J Pathol; 2018; 69(2):157-168. PubMed ID: 30351863
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of p53 expression in hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients receiving neoadjuvant chemotherapy.
Albinsaad LS; Kim J; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Ahn SH; Lee SB
Breast Cancer Res Treat; 2021 Jun; 187(2):447-454. PubMed ID: 33599867
[TBL] [Abstract][Full Text] [Related]
38. Targeted Intraoperative Radiotherapy Tumour Bed Boost During Breast Conserving Surgery after Neoadjuvant Chemotherapy in HER2 Positive and Triple Negative Breast Cancer.
Kolberg HC; Loevey G; Akpolat-Basci L; Stephanou M; Fasching PA; Untch M; Bulsara M; Vaidya JS; Liedtke C
Rev Recent Clin Trials; 2017; 12(2):93-100. PubMed ID: 28155607
[TBL] [Abstract][Full Text] [Related]
39. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas.
Karihtala P; Kauppila S; Soini Y; Arja-Jukkola-Vuorinen
BMC Cancer; 2011 Jun; 11():262. PubMed ID: 21693047
[TBL] [Abstract][Full Text] [Related]
40. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
